An Eli Lilly drug helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker said in a news release Thursday.
The results add to evidence that the drug, tirzepatide — which is sold under the brand name Mounjaro for Type 2 diabetes — can be used as an effective weight loss aid.
Results from another trial released last year found that tirzepatide helped patients without Type 2 diabetes lose 22.5% of their body weight on average, or about 52 pounds. Patients in that trial had obesity or were overweight.
Read this story in its entirety on nbcnews.com.